How can you ensure patients are reporting side effects?

FAQ Library published on May 9, 2013 in Response Assessment, Comorbidities/SEs
Download Transcript Download Audio
Robert Z. Orlowski, MD, PhD
Professor, Chair Ad Interim
Department of Lymphoma/Myeloma
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Thank you for joining me. My name is Robert Orlowski, I am a professor in the Department of Lymphoma and Myeloma and in the Department of Experimental Therapeutics, and the director of the Myeloma Section at University of Texas MD Anderson Cancer Center. One of the questions that I frequently am asked is, “What are some tips about ways that can be used to ensure that patients report all of the side effects that they are feeling while they are on chemotherapy?” And there is a number of approaches that we use at MD Anderson which I think may be very helpful to you as well. One is to make sure that both the nurses and the doctors, as well as other health care professionals involved in the patient’s care ask these questions, because the more questions that are asked, the greater is the likelihood that we will be able to capture all of the side effects that are occurring. Another one is to make sure to reassure the patient that even if a dose reduction is needed, or if one of the drugs that they are getting which is causing a side effect needs to be stopped, that their outcome can still be excellent. Just as one example, we know from the bortezomib literature that patients who have a dose reduction due to neuropathy still have excellent outcomes, and oftentimes I think patients worry that if they report a side effect, we are going to stop their therapy and that will influence their outcome. Fortunately we know now that in fact that is not the case. And finally, I think it is effective to remind patients that if they are on a drug that for some reason they cannot tolerate, because of the number of options are now available which are much greater than was the case before, the chances are that you will be able to find a different drug that the patient can tolerate, which hopefully the myeloma will tolerate very poorly, leading to the optimal outcome, which is maximal reduction in the myeloma with a minimal reduction in the patient’s quality of life.

Reviewed on January 17, 2017 for clinical relevance.

Last modified: February 8, 2017
Related Items by Category
What is 'stable disease' in multiple myeloma?
FAQ Library published on March 6, 2013 in Response Assessment, General Education
What constitutes a very good partial response in multiple myeloma?
FAQ Library published on March 6, 2013 in Response Assessment, General Education
What is the difference between complete response and stringent complete response?
FAQ Library published on March 4, 2013 in Response Assessment, General Education
How do I manage the side effects of stem cell transplantation?
FAQ Library published on January 9, 2013 in Stem Cell Transplant, Comorbidities/SEs
What are the common side effects of melphalan?
FAQ Library published on August 30, 2012 in Comorbidities/SEs
What are the common side effects of bortezomib?
FAQ Library published on August 23, 2012 in Comorbidities/SEs
What are the most common side effects of pomalidomide?
FAQ Library published on August 16, 2012 in Comorbidities/SEs
What are the most common side effects of carfilzomib?
FAQ Library published on August 9, 2012 in Comorbidities/SEs
What are the side effects of bendamustine?
FAQ Library published on August 2, 2012 in Comorbidities/SEs
What are the most common side effects of lenalidomide therapy?
FAQ Library published on July 26, 2012 in Comorbidities/SEs, Nurses & Pharmacists
Related Items by Author
What are the major side effects associated with daratumumab in combination with bortezomib-dexamethasone, and the best ways to manage them?
Robert Z. Orlowski, MD, PhD
FAQ Library published on September 20, 2017
What are the major toxicities associated with daratumumab in combination with lenalidomide-dexamethasone, and the best ways to manage them?
Robert Z. Orlowski, MD, PhD
FAQ Library published on September 6, 2017
When do you use daratumumab with lenalidomide/dexamethasone or bortezomib/dexamethasone in practice?
Robert Z. Orlowski, MD, PhD
FAQ Library published on April 12, 2017
How would you define and treat a myeloma patient with aggressive symptomatic relapse?
Robert Z. Orlowski, MD, PhD
FAQ Library published on February 8, 2017
What drug regimens are recommended for asymptomatic biochemical relapse with slow rise M-protein?
Robert Z. Orlowski, MD, PhD
FAQ Library published on January 25, 2017
How should you choose between carfilzomib and ixazomib?
Robert Z. Orlowski, MD, PhD
FAQ Library published on September 27, 2016
Which patients benefit from a doublet vs. a triplet salvage regimen?
Robert Z. Orlowski, MD, PhD
FAQ Library published on September 8, 2016
Why should a myeloma patient who has a previous history of bone lesions have a bone study as part of current response assessment?
Robert Z. Orlowski, MD, PhD
FAQ Library published on March 15, 2016
What is the difference between CR and MRD?
Robert Z. Orlowski, MD, PhD
FAQ Library published on June 4, 2015
What is the CyBorD regimen's safety and efficacy as a primary therapy?
Robert Z. Orlowski, MD, PhD
FAQ Library published on May 9, 2013 in Induction Therapy, Emerging Therapeutics